argenx (ENXTBR:ARGX) Stock Looks Rich Despite Its 210% Five Year Run

Argenx stock has delivered very strong gains over the past five years, yet current valuation checks suggest investors are paying a premium rather than buying into an obvious bargain.

• A 209.7% return over 5 years points to a stock where expectations have risen sharply and pricing now embeds a lot of optimism.

• Positive Phase 3 data for Vyvgart Hytrulo in autoimmune myositis can support high growth expectations, while execution and clinical risk around expanding the immunology pipeline may limit how much investors are willing to pay.

• A mixed value profile, with a value score of 3.0, signals that argenx is not clearly cheap or clearly expensive once broader valuation checks are taken into account.

For investors, the debate is whether argenx’s current price already reflects the promise of its immunology portfolio and recent acquisitions or still leaves room for further upside.

Spot screener containing 610 high quality undiscovered gems that, like argenx, combine ambitious pipelines with recent momentum yet remain off many investors’ radar.

Is argenx Getting Expensive on Earnings?

The P/E ratio is a useful check for argenx because it links today’s share price directly to the company’s current earnings base. Argenx trades on a P/E of 38.5x, which is above the broader biotech industry average of 25.8x yet below the peer group average of 52.4x. That places the stock in the higher priced part of the sector, but not at the very top end compared with closer peers.

On Simply Wall St’s fair P/E estimate of 29.1x, which blends factors such as growth profile, risk and market positioning, argenx screens as overvalued on earnings. The current 38.5x multiple is meaningfully above that reference point, suggesting investors are paying up for the Vyvgart franchise and the expanded immunology pipeline following the Forte Biosciences acquisition and recent Phase 3 success in autoimmune myositis. The stock therefore appears overvalued on its current P/E multiple, with earnings already carrying a clear premium to the modelled fair level.

See what the numbers say about this price — find out in our valuation breakdown.

The argenx Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives for argenx pick up where this valuation puzzle leaves off and spell out what kind of growth, margins and earnings path would need to play out for the stock to be worth materially more or less than today’s price, using frameworks that live on the company’s Community page. Rather than relying on a single multiple or model, each Narrative lays out the assumptions behind its view of fair value so you can compare them with argenx’s actual results over time.

The community is split on argenx, with one camp arguing recent Vyvgart milestones leave the stock undervalued while others see expectations running ahead of fundamentals.

Bull case: 24% undervalued

“With a best-in-class global supply chain, $3.9 billion in cash, and operational discipline, argenx has the financial strength to execute on accelerated pipeline development and potential M&A, positioning it to emerge as the dominant rare autoimmune biologics leader and driving sustainable multi-year earnings outperformance…”

Read the full Bull Case to see why argenx could be undervalued

Bear case: 32% overvalued

“If pipeline fails or pricing pressure intensifies, this could create material downside risk…”

Read the full Bear Case to see why argenx could be overvalued

Do you think there’s more to the story for argenx? Head over to our Community to see what others are saying!

The Bottom Line

For argenx, current market multiples lean toward overvalued, which suggests the stock already reflects a generous view of its earnings power and pipeline prospects. The mixed overall value profile reinforces that this is not a clear-cut bargain, nor an obvious excess to fade, but a stock where opinions are likely to stay split. What really decides the outcome from here is whether argenx can convert its immunology portfolio and recent clinical wins into durable earnings growth that justifies the premium investors are currently paying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ARGX.BR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com